PMID- 20420820
OWN - NLM
STAT- MEDLINE
DCOM- 20100927
LR  - 20240507
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 638
IP  - 1-3
DP  - 2010 Jul 25
TI  - Reduction of periductal fibrosis in liver fluke-infected hamsters after long-term 
      curcumin treatment.
PG  - 134-41
LID - 10.1016/j.ejphar.2010.04.018 [doi]
AB  - Chronic infection with the liver fluke, Opisthorchis viverrini, induces advanced 
      periductal fibrosis and is a relative risk factor for cholangiocarcinoma in 
      Southeastern Asia. We examined the reducing effect of curcumin on hepatobiliary 
      fibrosis using O. viverrini-infected hamsters supplemented with dietary 1% 
      curcumin (w/w) as an animal model. The expression profile of matrix 
      metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs), cytokines, and 
      collagens was assessed in relation to liver fibrosis. Histopathological studies 
      revealed that curcumin had no effect on fibrosis at the short-term infection (21 
      days and 1 month); however, peribiliary fibrosis was significantly reduced after 
      the long-term curcumin treatment for 3 months, compared to the untreated group. 
      Expression of alpha-smooth muscle actin was associated with the reduction of 
      liver fibrosis. A decrease in hepatic hydroxyproline level and mRNA expression of 
      collagen I and III supported the reduction of fibrosis. The expression of TIMP-1, 
      TIMP-2, and tumor necrosis factor-alpha genes was also decreased after curcumin 
      treatment. In contrast, curcumin increased mRNA expression of MMP-13, MMP-7 (at 6 
      months), interleukin-1 beta, and transforming growth factor beta, implying that 
      increased MMPs activity contributes to extracellular matrix degradation. These 
      results suggest that curcumin reduces periductal fibrosis after long-term 
      treatment by tissue resorption via inhibition of TIMPs expression and enhancement 
      of MMPs expression mediated by cytokines. In conclusion, curcumin may serve as a 
      promising nutraceutical agent exerting antifibrotic effect in O. 
      viverrini-infected patients and contribute to cholangiocarcinoma prevention.
CI  - (c) 2010 Elsevier B.V. All rights reserved.
FAU - Pinlaor, Somchai
AU  - Pinlaor S
AD  - Department of Parasitology, Faculty of Medicine, Khon Kaen University, Khon Kaen 
      40002, Thailand. psomec@kku.ac.th
FAU - Prakobwong, Suksanti
AU  - Prakobwong S
FAU - Hiraku, Yusuke
AU  - Hiraku Y
FAU - Pinlaor, Porntip
AU  - Pinlaor P
FAU - Laothong, Umawadee
AU  - Laothong U
FAU - Yongvanit, Puangrat
AU  - Yongvanit P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100424
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Actins)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - 0 (Tissue Inhibitor of Metalloproteinases)
RN  - 0 (Transforming Growth Factor beta)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2)
RN  - 9007-34-5 (Collagen)
RN  - EC 3.4.24.- (Matrix Metalloproteinases)
RN  - IT942ZTH98 (Curcumin)
RN  - RMB44WO89X (Hydroxyproline)
SB  - IM
MH  - Actins/biosynthesis
MH  - Animals
MH  - Collagen/biosynthesis
MH  - Cricetinae
MH  - Curcumin/*administration & dosage/pharmacology
MH  - Drug Administration Schedule
MH  - Gene Expression Regulation/drug effects
MH  - Hydroxyproline/metabolism
MH  - Inflammation/drug therapy
MH  - Interleukin-1beta/biosynthesis
MH  - Liver Cirrhosis/*drug therapy
MH  - Liver Cirrhosis, Experimental/*drug therapy/immunology/metabolism/pathology
MH  - Male
MH  - Matrix Metalloproteinases/biosynthesis
MH  - Opisthorchiasis/*drug therapy
MH  - Tissue Inhibitor of Metalloproteinase-1/biosynthesis
MH  - Tissue Inhibitor of Metalloproteinase-2/biosynthesis
MH  - Tissue Inhibitor of Metalloproteinases/biosynthesis
MH  - Transforming Growth Factor beta/biosynthesis
MH  - Tumor Necrosis Factor-alpha/biosynthesis
EDAT- 2010/04/28 06:00
MHDA- 2010/09/29 06:00
CRDT- 2010/04/28 06:00
PHST- 2009/12/13 00:00 [received]
PHST- 2010/03/18 00:00 [revised]
PHST- 2010/04/12 00:00 [accepted]
PHST- 2010/04/28 06:00 [entrez]
PHST- 2010/04/28 06:00 [pubmed]
PHST- 2010/09/29 06:00 [medline]
AID - S0014-2999(10)00326-2 [pii]
AID - 10.1016/j.ejphar.2010.04.018 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2010 Jul 25;638(1-3):134-41. doi: 10.1016/j.ejphar.2010.04.018. 
      Epub 2010 Apr 24.